Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For people joining the study going forward (prospective group):
- People who have recently been diagnosed with a type of aggressive blood cancer called Diffuse Large B Cell Lymphoma and are starting their first course of standard treatment
- People who are able to give written consent to participate in the study
- People for whom a preserved tissue sample (a small piece of tissue stored in a special wax-like material) is available
For people whose past medical records are being reviewed (retrospective group):
- People who were diagnosed with Diffuse Large B Cell Lymphoma between 2011 and 2017
- People for whom a preserved tissue sample and relevant medical records are available
Who may not be able to join:
- People who are already taking part in another clinical trial may not be eligible for this study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Gerardo Musuraca, MD, IRST IRCCS
Phone: +39 0543739100
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
identification of new prognostic biomarkers
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.